Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Proffered Paper Session 1

195 - CC-122, a Novel Cereblon-Modulating Agent, in Combination With Obinutuzumab (GA101) in Patients With Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL)

Date

05 Mar 2018

Session

Proffered Paper Session 1

Presenters

Jean-Marie Michot

Citation

Annals of Oncology (2018) 29 (suppl_3): iii7-iii9. 10.1093/annonc/mdy048

Authors

J. Michot1, R. Bouabdallah2, J.K. Doorduijn3, U. Vitolo4, M.J. Kersten5, A. Chiappella4, P.L. Zinzani6, M. Pourdehnad7, Z. Nikolova8, V. Ribrag9

Author affiliations

  • 1 Institut Gustave Roussy, 94 805 - - Villejuif/FR
  • 2 Institute Paoli Calmettes, Marseille/FR
  • 3 Erasmus MC Cancer Institute, Rotterdam, Netherlands, on behalf of the Lunenburg Lymphoma Phase I/II Consortium (LLPC), Rotterdam/NL
  • 4 Azienda Ospedaliera Universitaria Città della Salute e della Scienza di Torino, Torino/IT
  • 5 Academic Medical Center, Amsterdam, Netherlands; on behalf of the Lunenburg Lymphoma Phase I/II Consortium (LLPC), Amsterdam/NL
  • 6 Institute of Hematology "Seràgnoli," University of Bologna, Bologna/IT
  • 7 Celgene Corporation, San Francisco/US
  • 8 Celgene Institute for Translational Research Europe, Sevilla/ES
  • 9 Institut Gustave Roussy, Villejuif/FR
More

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 195

Patients (pts) with NHL experiencing early relapse (ER) within two years of initial diagnosis and those double refractory (DR) to both rituximab and chemotherapy have particularly poor outcomes (Casulo et al JCO 2015; Gopal et al. NEJM 2014). Preliminary results from CC-122-NHL-001, the first study of CC-122, a novel cereblon-modulating agent, in combination with obinutuzumab (G), showed promising response rates in pts with R/R B-cell NHL (Michot et al Blood 2016). Herein, we report updated results for safety and efficacy from CC-122-NHL-001 (NCT02417285) with further 12 months follow up.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings